Navigation Links
Diabetes drug linked to increased risk of heart failure
Date:8/20/2009

Rosiglitazone, a drug used to treat type 2 diabetes, is associated with an increased risk of heart failure and death among older patients compared to a similar drug (pioglitazone), concludes a study published on bmj.com today.

As such, the researchers say it is difficult to advocate continued use of rosiglitazone for most patients.

Rosiglitazone and pioglitazone belong to a class of drugs called thiazolidinediones and are widely used for the treatment of type 2 diabetes. They help to control blood sugar levels, but both drugs can also cause side effects including weight gain, fluid retention and heart failure.

It is unclear whether there are clinically important differences in the cardiac safety of these two drugs, so researchers in Canada compared the risk of heart attack, heart failure and death in patients treated with rosiglitazone and pioglitazone.

Using prescription records, they identified nearly 40,000 patients aged 66 years and older who started treatment with either rosiglitazone or pioglitazone between April 2002 and March 2008.

Data on hospital admission for either a heart attack or heart failure during the six-year study period were recorded and deaths were identified from a national database.

Detailed analysis showed that patients treated with pioglitazone had a significantly lower risk of heart failure and death compared to patients treated with rosiglitazone, but there was no significant difference in the risk of heart attack.

The researchers estimate that, for every 93 patients treated with rosiglitazone rather than pioglitazone, one additional cardiovascular event or death would be predicted to occur annually.

"Our findings suggest clinically important differences in the cardiovascular safety profiles of rosiglitazone and pioglitazone in clinical practice," say the authors. "Given the accumulating evidence of harm with rosiglitazone treatment and the lack of a distinct clinical advantage for the drug over pioglitazone, it is reasonable to question whether ongoing use of rosiglitazone is justified," they conclude.

This study reinforces the message that thiazolidinediones should be avoided in heart failure patients, but the claim that pioglitazone is safer than rosiglitazone is not fully supported by the data, say two experts from the Universities of Bath and Surrey in an accompanying editorial.

Although it may be tempting to move away from prescribing thiazolidinedione altogether, they write, long term follow-up data for newer products are not yet available.

Given that randomised trials are unlikely ever to provide the full picture, they suggest that enhancements to healthcare databases coupled with well designed studies like this one are essential for determining the full risk-benefit profile of medicines. People who have concerns regarding their diabetes treatment are urged to consult their GP and not to discontinue taking their medication.


'/>"/>

Contact: Emma Dickinson
edickinson@bmj.com
44-207-383-6529
BMJ-British Medical Journal
Source:Eurekalert

Related medicine news :

1. Type 1 diabetes linked to immune response to wheat
2. Exsulin Corporation Announces Publication of Phase 2 Trial Results for Novel Islet Regeneration Treatment in Type 1 & Type 2 Diabetes
3. Scarring key to link between obesity and diabetes
4. Dwayne Johnson, Novo Nordisk and the Entertainment Industry Foundation Educate Families about Healthy Living and Diabetes
5. The Jones Center for Diabetes & Endocrine Wellness Selects Retasure to Enhance Diabetes Care
6. Found: A gene that may play a role in type 1 diabetes
7. Taking the needles sting out of diabetes
8. Cell Conversion Shows Promise for Diabetes Treatment
9. AADE, Emory University and Johnson & Johnson Diabetes Institute Partner to Educate and Improve Access to Care for Atlanta-area Minorities with Diabetes
10. Sex Hormone Protein May Predict Type 2 Diabetes
11. BD and Direct Relief International Team Up to Provide Free Diabetes Insulin Injection Products to Americans Impacted by the Economic Downturn
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2017)... (PRWEB) , ... July 23, ... ... Eating Disorders Professionals ™(iaedp), the leading provider of education and training standards ... in preparation for competency for Traditional Certification: the iaedp™ Core Curriculum. , ...
(Date:7/23/2017)... ... 23, 2017 , ... Scientists from the University of Exeter reported ... weight-bearing activity equivalent to a medium-paced run for pre-menopausal women, or a slow jog ... in total spine care, I understand the importance exercise can play on improving bone ...
(Date:7/23/2017)... TORONTO, ONTARIO, CANADA (PRWEB) , ... July 23, 2017 , ... ... as a way to gain that elusive college scholarship or even go on to ... Sports Medicine’s Annual Meeting in Toronto, Canada today say “not so fast.” ...
(Date:7/23/2017)... ... , ... “I Am Not Nothin’: The Serpent Handler’s Daughter” is a compelling ... write and a brokenhearted young soldier who turned to whiskey after his return from ... power of simple faith is the work of published author Tommy G. Robertson, a ...
(Date:7/23/2017)... ... July 23, 2017 , ... “Squiggy’s Outdoor Adventure”: a turtle’s backyard adventure that ... of published author, Paula Christian, a wife and mother to three amazing, and supportive, ... center their lives on God. She loves to tell stories to her children, ...
Breaking Medicine News(10 mins):
(Date:7/21/2017)... YORKTOWN, N.Y. and EDMONTON, ... IBM ) scientists and the University of ... have published new data in Nature,s partner journal, ... learning algorithms helped predict instances of schizophrenia with ... technology predicted the severity of specific symptoms in ...
(Date:7/20/2017)... PAUL, Minn. , July 20, 2017  Prime Therapeutics ... Jonathan Gavras , M.D., following today,s Institute for Clinical ... report on the effectiveness and value of abuse-deterrent ... manager on the policy roundtable at the meeting. ... is not a material cost benefit to the use of ...
(Date:7/14/2017)... Endo International plc (NASDAQ: ENDP ) will announce its ... its senior management team will host a conference call and webcast ... The dial-in number to access the call is U.S./ ... passcode is 45397076. Please dial in 10 minutes prior to the ... replay of the call will be available from August 8, 2017 ...
Breaking Medicine Technology: